For Your Kitchen
Cookbooks

Everyday recipes with room for flavor, variety, and real life. Dinner should not feel like homework.

Taste it

Sponsorship complete. Dine on...

Nutrition, wellness, weight loss, and calmer healthy living.

Examining the Potential Cancer Risk of GLP-1 Drugs Like Ozempic

Jul 13, 2026
Examining the Potential Cancer Risk of GLP-1 Drugs Like Ozempic

In the lead-up to the 2026 annual meeting of the American Society of Clinical Oncology, a surge of interest has emerged regarding GLP-1 drugs, particularly Ozempic, and their potential link to cancer risk. Headlines from major news outlets have suggested that these medications might lower cancer risk, prompting widespread discussion. However, the excitement surrounding this notion may be outpacing the available evidence. As a physician and clinical epidemiologist, I have been involved in designing and interpreting studies that assess the effects of commonly used drugs, including GLP-1 medications.

Cancer is notoriously difficult to study, as it encompasses a wide array of diseases, each with unique biological characteristics and risk factors. Consequently, the impact of a single drug on cancer risk is multifaceted, with some studies indicating an increased risk for certain cancers while others suggest a protective effect for different types.

For Your Kitchen
Cookbooks
Taste it
Kitchen Scales
Taste it
Meal Prep Containers
Taste it

Sponsorship complete. Dine on...

Initially, there were concerns that GLP-1 drugs could elevate cancer risk, particularly regarding thyroid cancer. Research in rodents indicated that Ozempic could lead to thyroid C cell tumors, prompting U.S. regulators to issue a black box warning in June 2026 for individuals with a personal or familial history of related conditions. However, it is important to note that human thyroid C cells are less susceptible to GLP-1 drugs compared to those in rodents, as they possess fewer GLP-1 receptors. Long-term studies in primates did not replicate the tumor growth observed in rodent studies.

A 2025 analysis of data from 93 clinical trials found no definitive link between GLP-1 drug use and thyroid cancer, a conclusion echoed by European regulators in 2023 following their review of the available research. Concerns also extended to pancreatic cancer, but a 2025 analysis of 62 studies similarly found no consistent evidence of increased risk associated with GLP-1 drugs.

While these findings provide some reassurance, they are provisional. GLP-1 drugs are relatively new, and cancer often takes years to develop. The conversation has shifted from whether these drugs might increase cancer risk to whether they could potentially prevent or treat cancer. A 2024 study involving over 1.6 million individuals with Type 2 diabetes indicated lower rates of 10 out of 13 obesity-related cancers among those treated with GLP-1 drugs compared to those receiving insulin. Another study in 2025 found a 17% reduction in overall cancer rates among GLP-1 drug users, with notable decreases in endometrial, ovarian, and meningioma cancers. However, the same study reported a 38% increase in kidney cancer risk among these patients, highlighting the need for further investigation.

A 2026 study involving over 110,000 women undergoing breast imaging suggested a 30% lower risk of breast cancer among GLP-1 drug users. Additionally, research on colon cancer patients indicated a significant difference in survival rates, with only 16% of those on GLP-1 drugs dying within five years compared to 37% of those not taking the medication. A report presented at the 2026 American Society of Clinical Oncology indicated a 34% lower risk of death across six cancer types for those on GLP-1 drugs.

Despite these promising findings, several factors complicate the interpretation of studies on GLP-1 drugs and cancer risk. One major issue is healthy user bias, where individuals who start GLP-1 therapy tend to be healthier and wealthier than those who do not. This disparity can skew observational studies, making it challenging to determine whether the drug itself or the patients' inherent advantages are responsible for lower cancer rates.

Another consideration is the choice of comparison drugs. The 2024 study's findings were based on comparisons with insulin, which is typically prescribed to patients with more advanced diabetes, a known cancer risk factor. When compared to metformin, another diabetes medication, the protective effect of GLP-1 drugs was not as evident.

Timing also plays a crucial role in understanding these studies. Cancer can take decades to develop, yet many GLP-1 studies only follow patients for a few years. Observed benefits appearing shortly after treatment initiation raise questions about whether these effects are genuinely due to the drug or if they reflect preexisting differences among patients.

Most of the research on GLP-1 drugs and cancer risk has been conducted in high-income countries, which raises concerns about the generalizability of these findings to lower-income populations where cancer burdens are increasing. Randomized trials, which can provide more reliable data by controlling for biases, are necessary to draw more definitive conclusions about the impact of GLP-1 drugs on cancer risk.

In summary, while current evidence suggests that GLP-1 drugs do not elevate overall cancer risk, the assertion that they actively prevent cancer or improve survival rates remains unproven. The relationship between these medications and cancer risk is complex and warrants further exploration. Until more robust data is available, it is prudent to approach claims regarding GLP-1 drugs and cancer risk with caution.

For Your Kitchen
Cookbooks
Taste it
Kitchen Scales
Taste it
Meal Prep Containers
Taste it
Vegetable Prep & Salad Spinners
Taste it

Sponsorship complete. Dine on...

For Your Kitchen
Cookbooks

Everyday recipes with room for flavor, variety, and real life. Dinner should not feel like homework.

Taste it
Kitchen Scales

Kitchen scales for recipes that deserve more precision than 'that looks about right.'

Taste it
Meal Prep Containers

Give tomorrow's lunch a proper home. Containers for meals worth looking forward to.

Taste it
Vegetable Prep & Salad Spinners

Salad spinners and vegetable-prep tools for everyday salads, bowls, and side dishes. A little less kitchen setup, a little more time to enjoy the meal.

Taste it
Blenders & Smoothie Tools

Blenders for fruit, yogurt, soups, and the combinations you actually enjoy. Everyday kitchen tools, not a promise in a glass.

Taste it
Sheet Pans & Roasting Essentials

Sheet pans and roasting racks for vegetables and simple oven meals. Useful equipment for dinner without an elaborate production.

Taste it

Sponsorship complete. Dine on...

Across our publications

In Other News

Latest stories from other publications.

Explore all publications (opens in a new tab)